Release details

2016-01-27 15:25 CET
  • Print
  • Share Share

Key information relating to the conditional repair issue to be carried out by Bionor Pharma ASA




Key information relating to the conditional repair issue to be carried out by Bionor Pharma ASA

(Oslo, Norway, 27 January 2016) Reference is made to the Company's announcement regarding completion of a private placement published earlier today. The private placement is conditional upon approval by the shareholders in an extraordinary general meeting (the "EGM") to be held on 11 February 2016, see separate announcement published 21 January 2016.

The Board has proposed to complete a subsequent repair offering to existing shareholders who did not receive allocation in the private placement following completion of the private placement, see further details in the notice of the EGM. Such repair offering is also subject to shareholder approval. Further, the repair issue is subject to a prospectus being approved by the Norwegian Financial Supervisory Authority and published by the Company. All details about the repair issue will be set out in the prospectus, expected to be published on or about 16 February 2016.

Key information in relation to the conditional repair issue:

Date on which the terms and conditions of the repair issue were announced: 27 January 2016
Last day including right: 26 January 2016
Ex-date: 27 January 2016
Record date: 28 January 2016
Date of approval: 11 February 2016
Maximum number of new shares: 44.4 million (final number to be determined on the basis of the VPS list on 28 January 2016 reflecting the shareholders on 26 January 2016 and announced on 29 January 2016).
Subscription price per share: NOK 0.71

This information is published in accordance with the requirements of the Continuing Obligations.

Further information
David Horn Solomon, President and CEO, +45 22 20 63 00,
Jens Krøis, CFO, +45 20 80 16 68,
Jørgen Fischer Ravn, VP Investor Relations & Communications, +45 20 30 39 03,

About Bionor
Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing its proprietary therapeutic vaccine Vacc-4x in combination with other medicines toward a functional HIV cure. The company believes it has first mover potential based on clinical results to date and early adoption of now recognized clinical strategy. In December 2015, Bionor announced that the HIV 'Shock & Kill' trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by significantly reducing latent HIV reservoir and further demonstrated control of viral load. Bionor is currently planning BIOSKILL, a proof-of-concept Phase II trial, which may lead to a major value inflection point and partnering opportunities. Bionor currently retains full ownership rights to Vacc-4x, i.e., the upside potential from partnering or licensing remains with the company. Bionor is based in Oslo, Norway, and also has offices in Copenhagen, Denmark and New York, USA. Bionor is listed on Oslo Børs (OSE:BIONOR). More information about Bionor is available at

Important information:
The release is not for publication or distribution, in whole or in part directly or indirectly, in or into Australia, Canada, Japan or the United States (including its territories and possessions, any state of the United States and the District of Columbia).

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. It is issued for information purposes only, and does not constitute or form part of any offer or solicitation to purchase or subscribe for securities, in the United States or in any other jurisdiction. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act. The Company does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering of the securities in the United States. Copies of this announcement are not being made and may not be distributed or sent into Australia, Canada, Japan or the United States. The issue, exercise, purchase or sale of subscription rights and the subscription or purchase of shares in the Company are subject to specific legal or regulatory restrictions in certain jurisdictions. Neither the Company nor the Manager assumes any responsibility in the event there is a violation by any person of such restrictions.

The distribution of this release may in certain jurisdictions be restricted by law. Persons into whose possession this release comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. The Manager is acting for the Company and no one else in connection with the Private Placement and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients or for providing advice in relation to the Private Placement and/or any other matter referred to in this release.